# Trial of VELCADE and Rituxan as Front-line Tx for Low-grade NHL

> **NCT00369707** · PHASE2 · COMPLETED · sponsor: **Northwestern University** · enrollment: 42 (actual)

## Conditions studied

- Non-Hodgkin's Lymphoma

## Interventions

- **DRUG:** Rituximab
- **DRUG:** bortezomib

## Key facts

- **NCT ID:** NCT00369707
- **Lead sponsor:** Northwestern University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-08-09
- **Primary completion:** 2012-05-22
- **Final completion:** 2014-10-10
- **Target enrollment:** 42 (ACTUAL)
- **Last updated:** 2019-09-06

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00369707

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00369707, "Trial of VELCADE and Rituxan as Front-line Tx for Low-grade NHL". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT00369707. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*